A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
CRESCENT BIOPHARMA, INC.
CBIO
$898M
Mkt Cap
$16.30
-4.29%
CRESCENT BIOPHARMA, INC. (CBIO) has a 5-year average return on invested capital (ROIC) of -114.9%. This is below average and may indicate limited pricing power.
CRESCENT BIOPHARMA, INC. (CBIO) has a market capitalization of $449M. It is classified as a small-cap stock.
CRESCENT BIOPHARMA, INC. (CBIO) does not currently pay a regular dividend.
CRESCENT BIOPHARMA, INC. (CBIO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CRESCENT BIOPHARMA, INC. (CBIO) generated $-72 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CRESCENT BIOPHARMA, INC. (CBIO) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
CRESCENT BIOPHARMA, INC. (CBIO) reported earnings per share (EPS) of $-2.42 in its most recent fiscal year.
Corporate Information We were incorporated under the laws of the State of Delaware in 2003. Our company, formerly known as GlycoMimetics, Inc., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc. (“Pre-Merger Crescent”). Prior to the reverse recapitalization transaction, Pre-Merger Crescent was established and incorporated under the laws of the state of Delaware on September 19, 2024. On June 16, 2025, in connection with the reverse recapitalization transaction with Pre-Merger Crescent, we changed our jurisdiction of incorporation from the state of Delaware to the Cayman Islands pursuant to a plan of conversion. We are a clinical-stage biotechnology company focused on delivering the next wave of transformative therapies to bring a brighter future for people living with cancer. We have a bold vision to build the next leading biotechnology oncology company.
| Segment | 2025 | % of Total |
|---|---|---|
Reportable Segment | $11M | 100% |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -152M | -133M | -38M | -37M | -47M | -63M |
| EPS | $-7.31 | $-2.42 | $-59.00 | $-58.00 | $-89.00 | $-123.00 |
| Free Cash Flow | -76M | -72M | -31M | -35M | -47M | -58M |
| ROIC | -69.4% | -118.6% | -173.2% | -96.1% | -108.8% | -77.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -175M | -153M | -40M | -39M | -47M | -63M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -82.9% | -142.3% | -173.2% | -96.1% | -108.8% | -77.7% |
| Shares Outstanding | 28M | 55M | 1M | 1M | 1M | 1M |
| Metric | 2017 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | 15M | 20M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 12M | 20M | 25M | 23M | 24M | 40M | 45M | 47M | 28M | 20M | 14M | 138M | 156M |
| SG&A | 2.9M | 6.6M | 7.8M | 8.7M | 9.8M | 11M | 17M | 17M | 19M | 19M | 18M | 25M | 31M |
| EBIT | -11M | -11M | -13M | -32M | -34M | -52M | -52M | -63M | -47M | -39M | -40M | -153M | -175M |
| Op. Margin | N/A | -74.1% | -63.7% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -11M | -11M | -13M | -32M | -33M | -48M | -51M | -63M | -47M | -37M | -38M | -133M | -152M |
| Net Margin | N/A | -74.0% | -63.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | -1K | -8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16M | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | N/M | -41.4% | -28.0% | -84.0% | -27.8% | -24.0% | -39.8% | -77.7% | -108.8% | -96.1% | -173.2% | -118.6% | -69.4% |
| ROE | -137.4% | -41.4% | -28.0% | -84.0% | -27.8% | N/A | -39.8% | -77.7% | -108.8% | -96.1% | -173.2% | -142.3% | -82.9% |
| ROA | -395.2% | -35.6% | -24.2% | -70.0% | -25.9% | -22.5% | -35.7% | -67.2% | -90.1% | -81.4% | -134.3% | -96.7% | -76.5% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -16M | -4.3M | -8.2M | -30M | -30M | -43M | -39M | -57M | -46M | -35M | -31M | -72M | -75M |
| Free Cash Flow | -16M | -4.5M | -8.5M | -30M | -30M | -43M | -39M | -58M | -47M | -35M | -31M | -72M | -76M |
| Owner Earnings | -16M | -6.1M | -11M | -33M | -34M | -48M | -46M | -64M | -51M | -39M | -36M | -85M | -93M |
| CapEx | 82K | 213K | 269K | 704K | 294K | 126K | 69K | 15K | 84K | 21K | 10K | 919K | 1.1M |
| Maint. CapEx | 133K | 159K | 191K | 191K | 264K | 275K | 271K | 265K | 207K | 153K | 35K | 84K | 148K |
| Growth CapEx | 0 | 54K | 77K | 514K | 31K | 0 | 0 | 0 | 0 | 0 | 0 | 835K | 918K |
| D&A | 133K | 159K | 191K | 191K | 264K | 275K | 271K | 265K | 207K | 153K | 35K | 84K | 148K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% | 0.0% | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% |
| Stock-Based Comp | 426K | 1.6M | 2.3M | 3.0M | 3.8M | 4.6M | 6.9M | 6.1M | 3.9M | 3.5M | 4.7M | 13M | 17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -271M | -179M | -95M | -83M | -21M | -212M | -189M |
| Cash & Equiv. | 2.3M | 55M | 47M | 40M | 124M | 210M | 137M | 90M | 48M | 42M | 11M | 213M | 189M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |
| Debt/Equity | 0.82 | 0.13 | 0.20 | 0.20 | 0.07 | N/A | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | -52.1 | -15.9 | -106.8 | -3209.6 | -66.3 | -16.5 | -42.8 | -69.9 | -69.9 |
| Equity | 2.9M | 51M | 40M | 35M | 120M | N/A | 128M | 82M | 43M | 38M | 5.3M | 203M | 184M |
| Total Assets | 5.3M | 57M | 48M | 42M | 129M | 215M | 143M | 94M | 52M | 45M | 11M | 240M | 199M |
| Total Liabilities | 2.4M | 6.5M | 8.0M | 7.1M | 8.9M | N/A | 15M | 13M | 8.9M | 6.9M | 5.8M | 37M | 15M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -63M | -74M | -87M | -119M | -152M | -201M | -309M | -373M | -420M | -456M | -494M | -172M | -195M |
| Working Capital | 2.6M | 50M | 39M | 34M | 119M | 204M | 126M | 79M | 42M | 37M | 5.3M | 201M | 181M |
| Current Assets | 4.9M | 56M | 47M | 41M | 127M | 212M | 138M | 91M | 51M | 44M | 11M | 237M | 196M |
| Current Liabilities | 2.3M | 6.5M | 7.7M | 6.3M | 8.2M | 8.8M | 12M | 12M | 8.9M | 6.8M | 5.8M | 36M | 14M |
| Per Share Data | |||||||||||||
| EPS | -22.18 | -1.50 | -1.68 | -3.75 | -113.00 | -118.00 | -112.00 | -123.00 | -89.00 | -58.00 | -59.00 | -2.42 | -7.31 |
| Owner EPS | -33.66 | -0.82 | -1.41 | -3.88 | -114.74 | -117.80 | -101.88 | -123.80 | -96.31 | -60.61 | -55.81 | -1.54 | -3.36 |
| Book Value | 6.08 | 6.85 | 5.31 | 4.16 | 406.43 | N/A | 281.43 | 158.25 | 81.83 | 60.38 | 8.28 | 3.68 | 6.67 |
| Cash Flow/Share | -32.49 | -0.58 | -1.08 | -3.50 | -101.07 | -105.92 | -86.13 | -111.49 | -88.56 | -54.83 | -48.44 | -1.30 | -5.52 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.5M | 7.4M | 7.6M | 8.5M | 0.3M | 0.4M | 0.5M | 0.5M | 0.5M | 0.6M | 0.6M | 55.1M | 27.6M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | -3.0 | -3.1 | -4.0 | N/A | N/A | -1.5 | -1.0 | 3.0 | 4.2 | N/A | 1.7 | 2.4 |
| Price/Sales | N/A | -12.8 | -7.8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -36.2% | -21.9% | N/A | -21.3% | -17.0% |
| Market Cap | N/A | -155M | -127M | -142M | 0 | 0 | -193M | -83M | 128M | 160M | 0 | 340M | 449M |
| Avg. Price | N/A | -1,036.39 | -822.95 | -713.89 | 0.00 | 0.00 | -385.72 | -278.82 | -38.98 | 176.41 | 0.00 | 18.45 | 16.30 |
| Year-End Price | N/A | -834.90 | -668.80 | -669.90 | 0.00 | 0.00 | -423.50 | -160.60 | 244.75 | 251.00 | 0.00 | 12.35 | 16.30 |
CRESCENT BIOPHARMA, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
CRESCENT BIOPHARMA, INC. (CBIO) has a return on equity (ROE) of -142.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 13 years of financial data for CRESCENT BIOPHARMA, INC. (CBIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CRESCENT BIOPHARMA, INC. (CBIO) has a book value per share of $3.68, based on its most recent annual SEC filing.